DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
AD1191123
Title:
Cell Communication in Antiestrogen Resistance
Report Date:
2022-10-01
Abstract:
More women die from the estrogen receptor positive (ER+) breast cancer subtype than from anyother. The proportion of early ER+ recurrences (=5 years since diagnosis) approaches that forall triple-negative breast cancers alone. Late recurrences (>5 years after diagnosis), theresult of dormancy, are most common in ER+ disease and can arise decades after the initialdiagnosis. Since recurrent breast cancers have escaped the effects of endocrine therapies,and are lethal, we will study endocrine resistance (Tamoxifen; Fulvestrant). Our primaryobjective is to identify what drives breast cancer growth and determine how to stop it. Wewill learn about why some breast cancers are aggressive and others are indolent, and why/howsome breast cancers lay dormant for years and then re-emerge.
Document Type:
Conference:
Journal:
Pages:
17
File Size:
2.72MB
Contracts:
Grants:
Distribution Statement:
Approved For Public Release
